Showing 7481-7490 of 8682 results for "".
- Study: Lipid that Aids Normal Skin Turnover May Help Psoriasishttps://practicaldermatology.com/news/study-lipid-that-aids-normal-skin-turnover-may-help-psoriasis/2457495/A lipid that helps keep skin cell turnover on track may help restore healthy turnover in psoriasis, investigators say. Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in th
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov
- Nanoparticulate-based Sunscreens May Not Be So Dangerous After Allhttps://practicaldermatology.com/news/nanoparticulate-based-sunscreens-may-not-be-so-dangerous-after-all/2457499/Zinc oxide nanoparticles used in sunscreen neither penetrate the skin nor cause cellular toxicity after repeated applications, according to a study out of University of Queensland (UQ) and University of South Australia, The
- Exuviance Introduces HA100 Micro-Filler Regimenhttps://practicaldermatology.com/news/exuviance-introduces-ha100-micro-filler-regimen/2457502/Exuviance is launching HA100 Micro-Filler Regimen, a two-step beauty regimen featuring new Micro-Cone Patches that delivers 1
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- Study: Fine Water Particle Sprays Improve Facial Skin Moisture for Hourshttps://practicaldermatology.com/news/study-fine-water-particle-sprays-improve-facial-skin-moisture-for-hours/2457515/Spraying fine water particles onto the face in winter, when skin is dry, improved skin hydration and softening, according to a new study in Skin Research & Technology. In addition, water retention remained co
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month/2457519/November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society (IHhS) wants the world to know that hyperhidrosis’ (Hh) uncontrollable, no-fault sweating can soak through clothing and water-damage electronics. This makes
- Mayne Pharma Acquires FDA-approved Halobetasol Foamhttps://practicaldermatology.com/news/mayne-pharma-acquires-fda-approved-halobetasol-foam/2457520/Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for an investment of up to $32 million (comprising $10 million in cash up front, $5 million at commercial launch plus continge